- Home
- CLCO vs XOMA Comparison
CLCO vs XOMA Comparison
Compare CLCO & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- XOMA
- Stock Information
- Founded
- CLCO 2018
- XOMA 1981
- Country
- CLCO United Kingdom
- XOMA United States
- Employees
- CLCO N/A
- XOMA N/A
- Industry
- CLCO
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- CLCO
- XOMA Health Care
- Exchange
- CLCO Nasdaq
- XOMA Nasdaq
- Market Cap
- CLCO 503.8M
- XOMA 457.6M
- IPO Year
- CLCO N/A
- XOMA N/A
- Fundamental
- Price
- CLCO $9.55
- XOMA $36.35
- Analyst Decision
- CLCO
- XOMA Strong Buy
- Analyst Count
- CLCO 0
- XOMA 2
- Target Price
- CLCO N/A
- XOMA $69.50
- AVG Volume (30 Days)
- CLCO 340.2K
- XOMA 54.2K
- Earning Date
- CLCO 11-19-2025
- XOMA 11-06-2025
- Dividend Yield
- CLCO 6.28%
- XOMA N/A
- EPS Growth
- CLCO N/A
- XOMA N/A
- EPS
- CLCO 1.04
- XOMA N/A
- Revenue
- CLCO $322,034,000.00
- XOMA $44,952,000.00
- Revenue This Year
- CLCO $3.27
- XOMA $88.91
- Revenue Next Year
- CLCO N/A
- XOMA $13.80
- P/E Ratio
- CLCO $8.89
- XOMA N/A
- Revenue Growth
- CLCO N/A
- XOMA 194.98
- 52 Week Low
- CLCO $4.51
- XOMA $18.35
- 52 Week High
- CLCO $11.63
- XOMA $39.92
- Technical
- Relative Strength Index (RSI)
- CLCO 74.20
- XOMA 55.52
- Support Level
- CLCO $7.62
- XOMA $36.41
- Resistance Level
- CLCO $9.56
- XOMA $39.92
- Average True Range (ATR)
- CLCO 0.09
- XOMA 1.96
- MACD
- CLCO 0.06
- XOMA -0.31
- Stochastic Oscillator
- CLCO 98.72
- XOMA 58.26
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.